CRL-40,940, also referred to as flmodafinil, bisfluoromodafinil, and lauflumide, represents the bisfluoro derivative of modafinil. This compound falls under the category of eugeroics and functions as a mild dopamine reuptake inhibitor. Its developers assert that it exhibits superior efficacy to modafinil and adrafinil while presenting a reduced risk of side effects. CRL-40,940 was patented in 2013, and pre-clinical trials have been in progress since December 2015.
CRL-40,940, also known as flmodafinil, bisfluoromodafinil, and lauflumide, is a chemical compound and a derivative of modafinil. It is categorized as a eugeroic and functions as a weak dopamine reuptake inhibitor.
How does CRL-40,940 differ from modafinil and adrafinil?
CRL-40,940 is claimed by its inventors to be more effective than both modafinil and adrafinil while also having fewer associated side effects.
What is a eugeroic?
A eugeroic is a class of drugs that promotes wakefulness and alertness. They are often used to treat narcolepsy and excessive daytime sleepiness.
What are the potential applications of CRL-40,940?
CRL-40,940 is being explored in pre-clinical trials, and its potential applications may include treating sleep-related disorders and enhancing wakefulness and cognitive function.
Is CRL-40,940 available for medical or recreational use?
As of my knowledge, the cutoff date in September 2021, CRL-40,940, had not received regulatory approval for medical use. It is important to stay informed about its legal status in your region, as it may have changed since then.
Are there any reported side effects of CRL-40,940?
While its inventors claim fewer side effects than modafinil, it’s essential to consider that the safety profile of CRL-40,940 is still under investigation in pre-clinical trials. Potential side effects may become clearer as more research is conducted.
Where can I find more information about CRL-40,940?
To access comprehensive information about CRL-40,940, consider referring to scientific literature, research studies, and trustworthy sources. Additionally, stay updated on any developments regarding its regulatory status and potential medical applications.
CA 1199916: Lafon L, “Benzhydrylsulfinylacetamide derivatives,” published on January 28, 1986.
Cao J, Prisinzano TE, Okunola OM, Kopajtic T, Shook M, Katz JL, Newman AH (October 2010). “Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.” Published in ACS Medicinal Chemistry Letters, Volume 2, Issue 1, Pages 48–52. DOI: 10.1021/ml1002025. PMC: 3041981. PMID: 21344069.
US 20130295196: Konofal E, “Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof,” published on November 7, 2013.
“Flmodafinil Dosage: How Much Should You Take and When?” Accessed from modaforum.org. Retrieved on September 26, 2023.
Louis Lafon (December 18, 1984). “Patent US 4489095 A – Halogenobenzhydrylsulfinylacetohydroxamic acids.” Retrieved on July 25, 2015.